Rising Medication for ADHD Among Adults in the UK
The prevalence of medication use for Attention-Deficit Hyperactivity Disorder (ADHD) in the UK has seen a significant increase, particularly among adults in the last decade. This rise is particularly notable among women, with prescription rates tripling from 2010 to 2023.
Trends in ADHD Medication Use
Recent research reveals that the percentage of individuals prescribed ADHD medication has grown from 0.12% in 2010 to 0.39% in 2023. Most prominently, the figures for adults over 25 have surged, soaring from a mere 0.01% in 2010 to approximately 0.2% in 2023.
Academics at the University of Oxford have highlighted that this represents a more than 20-fold increase among women and a 15-fold increase among men in this demographic. The findings were derived from a comprehensive analysis of ADHD medication rates across several countries, including Belgium, Germany, the Netherlands, Spain, and the UK, involving data from nearly 200,000 individuals, of which over 31,000 were from the UK.
Increased Awareness and Diagnosis
The researchers reported a significant rise in ADHD medication use among adults, especially females, leading to their observation being published in The Lancet journal. They noted, “Among adults aged over 18, there was a two to 15-fold increase in prevalence of use during the study period, with the most pronounced increases observed in females, especially in the UK.” This trend underscores a growing awareness of ADHD’s presence in adults, particularly among women.
Context and Background
The study indicates that over 70% of individuals aged 25 and older in the UK and Spain had prior experience with antidepressants, suggesting potential overlaps in mental health treatments. Furthermore, the UK exhibited the largest relative rise in ADHD prescriptions compared to other nations in the study, with some increases also seen amongst younger populations aged three to 11 and teenagers.
Methylphenidate, marketed under various brand names like Ritalin and Concerta, has emerged as the foremost prescribed ADHD medication across the five countries analyzed.
Healthcare Concerns and Future Directions
The researchers have also pointed to a global shortage of ADHD medications that has persisted since September 2023. They argue that a better understanding of prescribing patterns could enable improved forecasting of demand, quicker responses, and a reduction in medicine shortages.
Health Secretary Wes Streeting announced in December that an independent review is underway to address the increasing demand for mental health, ADHD, and autism services. This review aims to investigate diagnosis rates and the adequacy of support systems available to patients.
Source: Original Article
